AETHLON MEDICAL closed at $5.75 on Nov 4, down 0.86%, 76.8% below its 52-week closing high. Volume of 16.0K shares was 0.27× its 20-day average (below normal).
Split-adjusted performance: -5.6% over one month, -51.7% over six months, -76.6% over one year.
Short interest was 32.9K shares at the Oct 15 settlement, down 56.4% from the prior report (4.7% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AEMDAETHLON MEDICAL | $5.75 | −0.86% | −51.7% | — | — | — | $4.1M | |
| NVNOenVVeno Medical | $7.00 | −2.43% | −30.5% | — | — | — | $4.9M | Compare |
| TNONTenon Medical | $1.91 | +1.06% | −92.7% | +126.8% | −316.7% | — | $5.1M | Compare |
| CODXCo-Diagnostics | $0.3614 | −4.89% | — | +2.0% | −3782.4% | — | $3.2M | Compare |
| AMIXAutonomix Medical | $1.61 | −3.01% | −80.1% | — | — | — | $3.2M | Compare |
| SNOASonoma Pharmaceuticals | $1.11 | −2.63% | −6.7% | +59.6% | −5.2% | — | $5.3M | Compare |
| INBSIntelligent Bio Solutions | $1.75 | −1.13% | −27.4% | +35.8% | −341.0% | — | $5.8M | Compare |
| BJDXBluejay Diagnostics | $2.29 | +3.62% | −69.7% | — | — | — | $2.6M | Compare |
| CNSYCerenome | $0.8916 | −31.42% | — | — | — | — | $6.8M | Compare |
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
